IMNM vs RLAY

Key Takeaways

• Immunome (IMNM) and Relay Therapeutics (RLAY) are both clinical-stage oncology biotechnology companies, but they target fundamentally different patient populations and therapeutic mechanisms.
• Immunome's lead asset, varegacestat, is under active FDA review with a target decision date of April 28, 2027 — placing the company potentially within a year of its first commercial product.
• Relay Therapeutics has delivered a roughly 398% one-year return as of late July 2026, significantly outpacing Immunome's approximately 110% gain over the same period, though both have comfortably outperformed the broader market.
• Both companies maintain strong balance sheets with cash runway extending into 2028, reducing near-term dilution risk, though RLAY carries notably higher short interest at approximately 19.5% of its float.
• The two stocks present a contrast between late-regulatory-stage execution (IMNM) and high-upside, earlier-commercial-horizon momentum (RLAY), making their comparison a useful lens for evaluating risk-reward in biotech.

Introduction

Biotechnology investors frequently face the challenge of comparing companies at different stages of clinical and regulatory maturity. IMNM and RLAY exemplify this dynamic. Both are oncology-focused firms with promising lead programs, deep pipelines, and substantial cash reserves, yet their risk profiles, recent stock trajectories, and near-term catalysts diverge significantly. This comparison is particularly relevant for traders and investors attempting to calibrate exposure to the high-reward, high-volatility biotechnology sector, where a single regulatory decision or clinical data readout can dramatically reshape valuations.

IMNM Overview and Recent Performance

Immunome, Inc. is a clinical-stage targeted oncology company headquartered in Bothell, Washington. The company develops first-in-class and best-in-class cancer therapies, with an emphasis on antibody-drug conjugates (ADCs) — a class of therapeutics that deliver potent cancer-killing agents directly to tumor cells. Immunome's most advanced program is varegacestat, an oral gamma secretase inhibitor for the treatment of desmoid tumors, a rare and locally aggressive soft-tissue condition. In April 2026, the company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), which was subsequently accepted for review with a Prescription Drug User Fee Act (PDUFA) target action date of April 28, 2027.

The NDA is supported by compelling Phase 3 RINGSIDE data showing an 84% reduction in the risk of disease progression or death compared to placebo, along with a 56% objective response rate. Beyond varegacestat, Immunome's pipeline includes IM-1021 (a ROR1-targeted ADC in Phase 1 for B-cell lymphoma), IM-1617 (a potential first-in-class solid tumor ADC that dosed its first patient in June 2026), and IM-3050 (an FAP-targeted radiotherapy). As of March 31, 2026, Immunome reported $582.7 million in cash and equivalents, funding operations into 2028. The stock has seen its market capitalization grow to approximately $2.5 billion in recent months, and its beta of 2.07 reflects elevated volatility relative to the broader market.

RLAY Overview and Recent Performance

Relay Therapeutics, Inc., based in Cambridge, Massachusetts, is a clinical-stage precision medicine company leveraging its proprietary Dynamo® platform — a computational and experimental drug discovery engine — to target proteins that have historically been difficult to address with small molecules. The company's lead asset is zovegalisib (RLY-2608), a first-in-class, pan-mutant, and isoform-selective PI3Kα inhibitor. Zovegalisib is being evaluated in the ongoing Phase 3 ReDiscover-2 trial for patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, a population that includes approximately 40% of HR+/HER2- advanced breast cancer patients.

The drug received FDA Breakthrough Therapy designation in February 2026, reflecting early clinical evidence of substantial improvement over available therapies. Updated Phase 1/2 data presented at the European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies Congress in March 2026 showed a median progression-free survival of 11.1 months and a confirmed objective response rate of 43% in heavily pre-treated patients. Relay's pipeline also extends into vascular anomalies and includes programs for NRAS-driven solid tumors and Fabry disease. The company's market capitalization has surged to roughly $4.0 billion, driven by a 398% one-year return as of late July 2026. However, short interest remains elevated at approximately 19.5% of the float, suggesting a meaningful segment of the market is betting against continued momentum.

Trending AI Robots

For traders seeking a data-driven edge in navigating volatile names like IMNM and RLAY, Tickeron's Trending AI Robots page offers a curated view of AI-powered trading bots designed to adapt to evolving market conditions. With hundreds of AI trading bots available on the platform — each employing distinct trading styles, strategies, timeframes, and performance profiles across thousands of tickers — only those demonstrating the strongest alignment with current market dynamics earn placement in the Trending section. These bots range from swing trading and trend-following models to intraday momentum strategies, with track records that can include annualized returns in the double digits and win rates exceeding 50%, depending on the bot and the strategy. For investors who want to complement their own analysis with algorithmic insight, exploring the Trending AI Robots page is a practical next step.

Head-to-Head Comparison

The most significant structural difference between these two stocks is regulatory proximity. Immunome already has an NDA under FDA review, with a definitive PDUFA date in April 2027. A positive outcome would transform the company from a pre-revenue biotech into a commercial-stage oncology firm. Relay Therapeutics, by contrast, is still enrolling its pivotal Phase 3 trial, meaning a potential commercial launch for zovegalisib is likely further out — though Breakthrough Therapy designation may accelerate the timeline.

From a momentum perspective, RLAY has dramatically outperformed IMNM over the past year, fueled by positive clinical data, the Breakthrough Therapy designation, and growing conviction around the PI3Kα-selective mechanism. Yet that outperformance has attracted substantial short interest, which could amplify volatility in either direction. IMNM's more moderate gain reflects a market that has already priced in much of the RINGSIDE data but is awaiting the binary FDA outcome. In terms of valuation, both stocks trade at steep premiums to their modest revenues, as is typical for pre-commercial biotech. IMNM's price-to-sales ratio sits above 500, while RLAY's is approximately 300 — neither metric is particularly meaningful for companies this early; investors are effectively underwriting the probability and size of future product revenues.

Risk profiles also differ. IMNM faces concentrated binary risk around the April 2027 FDA decision, while RLAY's risk is more distributed across clinical trial execution, the competitive landscape in PI3Kα inhibition, and the outcome of the ReDiscover-2 Phase 3 trial. Both companies benefit from cash positions that extend into 2028, affording them operational flexibility through their respective catalyst windows.

Tickeron AI Verdict

Based on observable market factors, Tickeron's AI-driven analytical framework would likely express a nuanced preference between these two names. For trend-following and momentum-oriented strategies, RLAY presents a more compelling profile: its 398% one-year return, strong upward trajectory above both 50-day and 200-day moving averages, and powerful clinical catalysts suggest sustained trend consistency. However, for risk-adjusted and catalyst-driven models, IMNM may be the more balanced candidate. Its near-term regulatory binary event offers a clearly defined timeline, the Phase 3 data is robust, and the company's diversified ADC pipeline provides downside protection beyond a single asset. The elevated short interest in RLAY also introduces a contrarian risk factor that probabilistic models would weigh carefully. In summary, momentum-oriented AI bots may lean toward RLAY, while stability-focused or catalyst-event models may favor IMNM — a reflection of the broader trade-off between upside potential and binary risk that defines this pairing.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations